Table 3.

Guideline recommendations pertaining to the use of rapid‐acting insulin analogues in pregnant patients with diabetes 35

Recommendations
●There is no evidence that either insulin aspart or insulin lispro has adverse effects on pregnancy or on the foetus
●Insulin lispro and insulin aspart have advantages over RHI during pregnancy
●lower risk of hypoglycaemia
●lower post‐prandial glucose excursions
●improved overall glycaemic control
●better patient satisfaction
●Insulin lispro and insulin aspart may offer benefits over NPH
●greater flexibility
●improved glycaemic control
●The use of insulin glulisine is not recommended because of a lack of relevant safety data

NPH, neutral protamine Hagedorn; RHI, regular human insulin